Intravenous palonosetron increases the incidence of QTc prolongation during sevoflurane general anesthesia for laparotomy

被引：5
作者：
Min, Jeong Jin [1 ]
Yoo, Yongjae [1 ]
Kim, Tae Kyong [1 ]
Lee, Jung-Man [1 ]
机构：
[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Anesthesiol & Pain Med, 101 Daehak Ro, Seoul 110744, South Korea
来源：
KOREAN JOURNAL OF ANESTHESIOLOGY | 2013年 / 65卷 / 05期
关键词：
Cardiac arrhythmia; Electrocardiography; General anesthesia; Palonosetron; Patient safety; Sevoflurane;
D O I：
10.4097/kjae.2013.65.5.397
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
Background: Palonosetron is a recently introduced 5-hydroxytryptamine- 3 (5-HT3) receptor antagonist useful for postoperative nausea and vomiting prophylaxis. However, 5-HT3 receptor antagonists increase the corrected QT (QTc) interval in patients who undergo general anesthesia. This retrospective study was performed to evaluate whether palonosetron would induce a QTc prolongation in patients undergoing general anesthesia with sevoflurane. Methods: We reviewed a database of 81 patients who underwent general anesthesia with sevoflurane. We divided the records into palonosetron (n = 41) and control (n = 40) groups according to the use of intraoperative palonosetron, and analyzed the electrocardiographic data before anesthesia and 30, 60, 90, and 120 min after skin incision. Changes in the QTc interval from baseline, mean blood pressure, heart rate, body temperature, and sevoflurane concentrations at each time point were compared between the two groups. Results: The QTc intervals at skin incision, and 30, 60, 90, and 120 min after the skin incision during general anesthesia were significantly longer than those at baseline in the two groups (P < 0.001). The changes in the QTc intervals were not different between the two groups (P = 0.41). However, six patients in the palonosetron group showed a QTc interval > 500 ms 30 min after skin incision, whereas no patient did in the control group (P = 0.01). No significant differences were observed between the two groups in mean blood pressure, body temperature, heart rate, or sevoflurane concentrations. Conclusions: Palonosetron may induce QTc prolongation during the early general anesthesia period with sevoflurane.
引用
收藏
页码：397 / 402
页数：6
相关论文
共 30 条
  • [1] Yang L.P., Scott L.J., Palonosetron: In the prevention of nausea and vomiting, Drugs, 69, pp. 2257-2278, (2009)
  • [2] Saito M., Tsukuda M., Review of palonosetron: Emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting, Expert Opin Pharmacother, 11, pp. 1003-1014, (2010)
  • [3] Gan T.J., Risk factors for postoperative nausea and vomiting, Anesth Analg, 102, pp. 1884-1898, (2006)
  • [4] Gan T.J., Meyer T., Apfel C.C., Chung F., Davis P.J., Eubanks S., Et al., Consensus guidelines for managing postoperative nausea and vomiting, Anesth Analg, 97, pp. 62-71, (2003)
  • [5] Park S.K., Cho E.J., A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting afer gynaecological laparoscopic surgery, J Int Med Res, 39, pp. 399-407, (2011)
  • [6] Moon Y.E., Joo J., Kim J.E., Lee Y., Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: A prospective, randomized, double-blind study, Br J Anaesth, 108, pp. 417-422, (2012)
  • [7] Candiotti K.A., Kovac A.L., Melson T.I., Clerici G., Joo G.T., A randomized, double-blind study to evaluate the efcacy and safety of three diferent doses of palonosetron versus placebo for preventing postoperative nausea and vomiting, Anesth Analg, 107, pp. 445-451, (2008)
  • [8] Kovac A.L., Eberhart L., Kotarski J., Clerici G., Apfel C., A randomized, double-blind study to evaluate the efcacy and safety of three diferent doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period, Anesth Analg, 107, pp. 439-444, (2008)
  • [9] Charbit B., Albaladejo P., Funck-Brentano C., Legrand M., Samain E., Marty J., Prolongation of QTc interval afer postoperative nausea and vomiting treatment by droperidol or ondansetron, Anesthesiology, 102, pp. 1094-1100, (2005)
  • [10] Ballard H.S., Bottino G., Bottino J., Ondansetron and chest pain, Lancet, 340, (1992)
123